What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Eric Van Cutsem mainly investigates Internal medicine, Surgery, Colorectal cancer, Oncology and Chemotherapy.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
His Surgery study which covers Placebo that intersects with Everolimus.
In most of his Colorectal cancer studies, his work intersects topics such as Epidermal growth factor receptor.
His Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Survival rate, Metastasis, Bevacizumab and Survival analysis.
His Chemotherapy study also includes
- Regimen that connect with fields like Radiation therapy,
- Tolerability that connect with fields like Pancreatic cancer.
His most cited work include:
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (4248 citations)
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (4132 citations)
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine (3192 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, Surgery and Placebo.
As a member of one scientific family, Eric Van Cutsem mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Phases of clinical research.
His studies in Oncology integrate themes in fields like Bevacizumab, Cetuximab, Fluorouracil and KRAS.
His Colorectal cancer research includes themes of Regimen and Clinical trial.
His Surgery study integrates concerns from other disciplines, such as Adverse effect and Hazard ratio.
The various areas that Eric Van Cutsem examines in his Placebo study include Tipiracil, Trifluridine, Clinical endpoint, Everolimus and Ramucirumab.
He most often published in these fields:
- Internal medicine (75.16%)
- Oncology (57.70%)
- Colorectal cancer (45.41%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (75.16%)
- Oncology (57.70%)
- Colorectal cancer (45.41%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, In patient and Cancer.
Eric Van Cutsem combines subjects such as Gastroenterology and Placebo with his study of Internal medicine.
His Placebo research incorporates elements of Clinical endpoint and Tipiracil.
His Oncology research includes elements of Gemcitabine, Clinical trial, Randomized controlled trial and Pancreatic cancer.
As part of his studies on Colorectal cancer, Eric Van Cutsem often connects relevant subjects like Microsatellite instability.
His research integrates issues of Trastuzumab and Confidence interval in his study of Chemotherapy.
Between 2018 and 2021, his most popular works were:
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (436 citations)
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer (277 citations)
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (158 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Colorectal cancer, Pembrolizumab and Cancer research.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His Gastroenterology study combines topics in areas such as Progression-free survival, Fluorouracil, Clinical endpoint, Hazard ratio and Performance status.
Eric Van Cutsem has included themes like Biomarker, Pancreatic cancer, Survival rate and Previously treated in his Oncology study.
His work deals with themes such as Binimetinib and Microsatellite instability, which intersect with Colorectal cancer.
Eric Van Cutsem focuses mostly in the field of Pembrolizumab, narrowing it down to topics relating to Gastroesophageal Junction and, in certain cases, Trastuzumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
